Read this module for insights and analysis on the most impactful multiple myeloma abstracts from the 2023 American Society of Hematology Annual Meeting by Sagar Lonial, MD, FACP, including thoughts on landmark clinical trials for anti-CD38 monoclonal antibodies in newly diagnosed multiple myeloma, bispecific antibodies, treatment of relapsed/refractory multiple myeloma with t(11;14) translocation, and smoldering myeloma.
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/ash-2023-multiple-myeloma/18449-27437
- Start Date: 2024-03-07 06:00:00
- End Date: 2024-03-07 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AbbVie (Any division) - Amount: 0.0 - Is Kind Support: False Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 0.0 - Is Kind Support: False Source: Seagen - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest